Adaptive Therapy

Phase 2Small molecule

TThe Christie NHS Foundation Trust

Adaptive Therapy is one of 5 small molecule programs targeting Tumour. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumourNot yet recruiting

TumourPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Tumour

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 2

1 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 3

Paxalisib

KKazia Therapeutics Limited

Phase 2

1 4

ASTX727

Taiho Oncology, Inc.

Phase 1

1 5

Adaptive Therapy

TThe Christie NHS Foundation Trust

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Tumour

NCT06470880

Clinical

Trials by Indication[1]

Tumour1 trial

Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

Not yet recruiting·TThe Christie NHS Foundation Trust·Phase 2·NCT06470880·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adaptive Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adaptive Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adaptive Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Christie NHS Foundation Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe Christie NHS Foundation Trust

Adaptive Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Tumour1 trial

References

Drug Info

Quick Facts

Related News